Sign in
Taking peopleNo phase

The Experience of Screening for SCID

Key facts

Who runs it
King's College London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
90 people, planned
Started
9 Nov 2022
Expected to end
31 Mar 2029
Type of study
Observational, 6 groups
Treatments tested
  • SCID Screening
Record updated
14 December 2022

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Participants must be at least 18 years of age. Participants must be able to understand the purpose and implications of the research study
  • Where participants are speakers of languages other than English, the research team will arrange a translator

Who cannot take part

  • Where a child dies after recruitment to the project the team will sensitively check whether the parents wish to continue participation to enable their views to be included

This trial is currently available in United Kingdom.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This project will evaluate the impact of including Severe Combined Immunodeficiency into the newborn bloodspot screening panel. It will recruit parents and health professionals primarily from the sites where this new form of screening is being trialled well as additional sites where clinicians will be involved in the care of these babies and comparator groups are needed.

Read full original descriptionShow less

The proposed work will consist of two work packages. The first, a mixed-methods study conducted with families from the point of screening information being returned through to the child's fifth birthday. The second, a qualitative interview study conducted with health professionals during the clinical evaluation phase of the national pilot programme.

The 6 groups in the trial

  • Positive NBS for SCID

    Parents whose baby was referred to an immunologist due their SCID screening result (minimum n= 10-25)

    Treatment: SCID Screening

  • Normal NBS result

    Parents who received a normal screening result (minimum n=10-25)

    Treatment: SCID Screening

  • False positive NBS result

    Parents who have received a false positive result elsewhere in screening (minimum n=2-10)

  • CFSPID Designation

    Parents who received a CFSPID result (minimum n=\~10)

  • SCID via family history or clinical presentation

    Parents whose baby was identified with SCID due to family history or clinical presentation (minimum n=10)

  • Parents whose babies have died

    Parents who have received an abnormal screening result (T cell receptor excision circles (TRECs) or who were identified with SCID due to family history or clinical presentation and whose baby has subsequently died (n=\~10)

    Treatment: SCID Screening

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploring Parents' and Health Professionals' Experiences of Screening for Severe Combined Immunodeficiency
Record updated
14 December 2022
The Experience of Screening for SCID (NCT05651113) – Frontlight Research